DrugPatentWatch Database Preview
Olmesartan medoxomil - Generic Drug Details
What are the generic sources for olmesartan medoxomil and what is the scope of olmesartan medoxomil patent protection?
Olmesartan medoxomil
is the generic ingredient in two branded drugs marketed by Daiichi Sankyo, Accord Hlthcare, Alembic Pharms Ltd, Alkem Labs Ltd, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Sciegen Pharms Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Pharms Usa Inc, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.There are thirty-six drug master file entries for olmesartan medoxomil. Twenty-seven suppliers are listed for this compound. There are four tentative approvals for this compound.
Summary for olmesartan medoxomil
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 14 |
| NDAs: | 14 |
| Drug Master File Entries: | 36 |
| Suppliers / Packagers: | 27 |
| Bulk Api Vendors: | 93 |
| Clinical Trials: | 68 |
| Patent Applications: | 4,755 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for olmesartan medoxomil |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for olmesartan medoxomil |
| DailyMed Link: | olmesartan medoxomil at DailyMed |
Pharmacology for olmesartan medoxomil
| Drug Class | Angiotensin 2 Receptor Blocker |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for olmesartan medoxomil
Synonyms for olmesartan medoxomil
| (5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate |
| (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-h |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-i midazole-5-carboxylate |
| (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-iMidazole-5-carboxylate |
| (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr |
| (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl]-1H-imidazole-5-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)imidazole-4-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate |
| (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate |
| (5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate |
| (5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate |
| (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazol-5-carboxylate; |
| (5-Methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate |
| (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate |
| (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate |
| 144689-63-4 |
| 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester |
| 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
| 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
| 5-(1-Hydroxy-1-methyl-ethyl)-2-propyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester |
| 5-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-3-[2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-3H-IMIDAZOLE-4-CARBOXYLIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER |
| 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
| 689O634 |
| 6M97XTV3HD |
| A808260 |
| AB0012006 |
| AB01275443_02 |
| AB01275443_03 |
| AB01275443-01 |
| AB1009487 |
| AC-1601 |
| AC1L2Y71 |
| AK-72894 |
| AKOS015894907 |
| AKOS015914772 |
| AN-1125 |
| AOB3863 |
| BC208264 |
| BC209016 |
| BCP9000555 |
| BDBM50442892 |
| Benevas |
| Benicar |
| Benicar (TN) |
| BENICAR HCT |
| Benicar, Olmetec,Olmesartan |
| Berlin-Chemie Brand of Olmesartan Medoxomil |
| Bio-0071 |
| BR-72894 |
| BRD-K78485176-001-02-9 |
| BSPBio_003491 |
| C29H30N6O6 |
| CAS-144689-63-4 |
| CCG-221184 |
| CCG-39596 |
| CHEBI:31932 |
| CHEBI:93384 |
| CHEMBL1200692 |
| CPD004727564 |
| Cs 866 |
| CS-0577 |
| CS-866 |
| CS-866DM |
| CS-866RN |
| CS866 |
| D01204 |
| D07UBG |
| DE-092 |
| DR003267 |
| DSSTox_CID_25924 |
| DSSTox_GSID_45924 |
| DSSTox_RID_81226 |
| DTXSID9045924 |
| EBD35964 |
| Forest Brand of Olmesartan Medoxomil |
| FT-0601603 |
| GTPL591 |
| HE311789 |
| HMS1922L15 |
| HMS2089K18 |
| HMS2093K16 |
| HMS3651E13 |
| HY-17005 |
| I06-0025 |
| I14-41691 |
| J-501595 |
| J10058 |
| KBio2_002490 |
| KBio2_005058 |
| KBio2_007626 |
| KBio3_002711 |
| KBioGR_001040 |
| KBioSS_002498 |
| KS-00000IVQ |
| KS-1182 |
| L001061 |
| LS-181818 |
| MCULE-2480015750 |
| MFCD00944911 |
| MLS006010109 |
| NCGC00095136-01 |
| NCGC00095136-02 |
| NCGC00095136-03 |
| NSC-758924 |
| NSC758924 |
| NU006784 |
| O0510 |
| Olmesartan (medoxomil) |
| Olmesartan medoximil |
| Olmesartan medoxomil (Benicar) |
| Olmesartan medoxomil (JAN/USAN) |
| Olmesartan medoxomil (JP17/USAN) |
| Olmesartan medoxomil [USAN:INN:BAN] |
| Olmesartan medoxomil for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Olmesartan medoxomil tablets (JP17) |
| Olmesartan medoxomil, >=98% (HPLC) |
| Olmesartan medoxomil, European Pharmacopoeia (EP) Reference Standard |
| Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material |
| Olmesartan medoxomil, United States Pharmacopeia (USP) Reference Standard |
| Olmesartan medoxomil|4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-carboxylic acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
| Olmesartanmedoxomil |
| Olmetec |
| Olmetec (TN) |
| Olmetec; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1Htetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
| Olsertain |
| Olvance |
| Openvas |
| Pharmakon1600-01505205 |
| RP17784 |
| S-1787 |
| s1604 |
| SAM001246634 |
| Sankyo Brand of Olmesartan Medoxomil |
| SBI-0206741.P001 |
| SC-17112 |
| SCHEMBL16403 |
| SMR002203616 |
| SPBio_000431 |
| Spectrum_001944 |
| SPECTRUM1505205 |
| Spectrum2_000506 |
| Spectrum3_001676 |
| Spectrum4_000740 |
| Spectrum5_001556 |
| SR-05000001987 |
| SR-05000001987-2 |
| ST24031498 |
| STL451024 |
| Tox21_111445 |
| UNII-6M97XTV3HD |
| UQGKUQLKSCSZGY-UHFFFAOYSA-N |
| votume |
| Z1550675457 |
| ZINC4149248 |
US Patents and Regulatory Information for olmesartan medoxomil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic Pharms Ltd | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 203012-002 | Apr 24, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Alembic Pharms Ltd | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 203012-003 | Apr 24, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Alembic Pharms Ltd | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 203012-001 | Apr 24, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Accord Hlthcare | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 207662-003 | Apr 24, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for olmesartan medoxomil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi Sankyo | BENICAR | olmesartan medoxomil | TABLET;ORAL | 021286-001 | Apr 25, 2002 | ➤ Sign Up | ➤ Sign Up |
| Daiichi Sankyo | BENICAR | olmesartan medoxomil | TABLET;ORAL | 021286-004 | Apr 25, 2002 | ➤ Sign Up | ➤ Sign Up |
| Daiichi Sankyo | BENICAR | olmesartan medoxomil | TABLET;ORAL | 021286-003 | Apr 25, 2002 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: